Minnesota · 2025-2026 Regular Session · Bill

HF 4852: Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council.

In committee Last action April 7, 2026: Introduction and first reading, referred to Health Finance and Policy

Plain-language summary

HF 4852 is a bill introduced in the Minnesota House on April 7, 2026. According to its official title, it concerns: Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council. Primary sponsor: Liz Reyer (Democratic-Farmer-Labor). It lists 1 additional sponsor. Most recent recorded action (April 7, 2026): Introduction and first reading, referred to Health Finance and Policy.

Sponsors

Primary sponsor: Liz Reyer (Democratic-Farmer-Labor). 1 co-sponsor.